Valuation: NovoCure Limited

Market Cap 1.64B 1.46B 1.35B 1.23B 2.32B 155B 2.35B 16.23B 6.36B 81.14B 6.15B 6.02B 259B P/E 2026 *
-11.4x
P/E 2027 * -17.2x
Enterprise Value 1.53B 1.36B 1.26B 1.15B 2.17B 145B 2.2B 15.18B 5.95B 75.92B 5.75B 5.63B 242B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.77x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day+0.96%
1 week-3.47%
Current month-10.92%
1 month-14.04%
3 months-10.86%
6 months+12.15%
Current year+9.89%
1 week 13.76
Extreme 13.76
14.75
1 month 13.76
Extreme 13.76
16.87
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
124.35
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

Head of Human Resources

1,905 0.0016%
30/06/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%-3.47%-1.87%-4.12% 1.64B
-0.44%+2.32%-19.56%+9.16% 181B
-0.90%+2.57%-1.70%+30.33% 116B
+0.17%+4.31%-22.67%+9.82% 113B
-2.30%+2.76%-51.96%-6.99% 79.83B
+0.04%+4.93%+4.19%+79.63% 65.06B
-0.27%+2.10%+15.54%+66.81% 54.35B
-0.68%+0.76%-0.35%-26.08% 52.23B
-0.63%+6.43%-13.33%+31.00% 44.15B
+0.02%+0.12%+25.71%-0.02% 32.47B
Average -0.40%+4.31%-6.60%+18.95% 74.02B
Weighted average by Cap. -0.56%+5.49%-12.31%+19.64%

Financials

2026 *2027 *
Net sales 726M 645M 598M 544M 1.03B 68.91B 1.04B 7.19B 2.82B 35.96B 2.73B 2.67B 115B 805M 715M 663M 603M 1.14B 76.38B 1.16B 7.97B 3.12B 39.86B 3.02B 2.96B 127B
Net income -142M -126M -117M -106M -201M -13.48B -204M -1.41B -551M -7.03B -533M -522M -22.42B -84.78M -75.36M -69.85M -63.55M -120M -8.05B -122M -840M -329M -4.2B -318M -311M -13.39B
Net Debt -105M -93.76M -86.9M -79.07M -149M -10.01B -152M -1.04B -410M -5.22B -396M -387M -16.65B -210M -187M -173M -157M -297M -19.92B -302M -2.08B -815M -10.4B -788M -771M -33.14B
Projected Income Statement - Annual - NovoCure Limited
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
19/10/26 US$14.21 +0.99% 49,211
16/10/26 US$14.07 -2.36% 1,287,702
15/10/26 US$14.41 +4.12% 1,810,878
14/10/26 US$13.84 -3.22% 1,186,007
13/10/26 US$14.30 -2.85% 772,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - NovoCure Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
14.07USD
Average target price
26.86USD
Spread / Average Target
+90.88%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NovoCure Limited
  1. Stock Market
  2. Stocks
  3. NVCR Stock